A preregistered note was made before retrieving prices, and this is not a backtest of a panel, but rather a generic price analysis. The analysis used 560 bars of GRAL data from June 12, 2024, to September 4, 2026, and 672 bars of SPY data from January 2024. The first 50 bars were excluded from the analysis to avoid early noise. A signal was generated when the close was higher than the prior 20 closes and the 50-day simple moving average, which is a calculation of the average price over a 50-day period. The signal triggered a buy order at the next open, with a stop loss set at 1 average true range, which is a measure of price volatility, and a target at 2 average true ranges. The analysis also included a 5-session timeout and no overlap between trades. A fee of 5 basis points, which is 0.05%, and slippage of 5 basis points were applied to each side of the trade. The results showed a return of 23.4898% and a drawdown, which is the peak-to-trough decline, of 26.8884% during the training period, and a return of -36.2152% and a drawdown of 39.0181% during the holdout period. The stress test, which is a simulation of extreme market conditions, applied a fee of 25 basis points and slippage of 25 basis points, resulting in a return of -42.5155% and a drawdown of 44.821%. The analysis used a standalone cash ledger and reconciled the results with a vectorbt explicit long-only orders, which is a type of trading strategy. The results were not affected by synthetic row ordering or observed minute execution. A news scan found the source of the data at https://runway.adityaperswal.workers.dev/data/stock-bars, and the artifacts and tests are available at artifacts/test.py and tests.json. The analysis used a specific version of the GRAL and SPY data, identified by the SHAs 9459602a452562126bbf0d5db729213359f239a125fdfcc1dca061757f2fd4d8 and 7ecf3b2c2b253af24930d116e16f2c6635dc8fe8049167b3687025121a34b1d6, respectively. The quarterly dates and panel probabilities were not retrofitted to the price history. This negative holdout result rejects this implementation, but not all catalyst run-ups.
The company's financial situation is as follows: as of June 30, the company had $861.609 million in cash and securities, and in the first half of the year, it had an operating cash flow of $167.719 million, plus $35 million in capital expenditures, which implies a monthly cash consumption of $28.109 million and 30.65 months of runway at the current burn rate. However, this is just a sensitivity analysis and not the company's official guidance, as launches, working capital, leases, interest, and sales can change. Management only asserts that the company has enough cash for at least 12 months and anticipates future financing. The company's Q2 GAAP gross margin was -28.12%, which includes $33.472 million in tangible amortization, a type of non-cash expense that represents the decrease in value of intangible assets over time. Excluding this amortization, the gross margin would be 46.78%, and excluding $0.649 million in stock-based compensation, or SBC, a type of non-cash expense that represents the value of stock awards given to employees, the adjusted gross margin would be 48.24%. Therefore, the statement that 'every test loses cash' is not supported. The company's total SBC was $19.557 million, which is 43.76% of revenue, and the year-to-date shares plus 10.75% are economic costs, meaning they have a real cost to the company, even if they are non-cash. The company's partnership with Samsung, which had $109.018 million in net cash, is real, but the $25.423 million commercial deferred asset was fully impaired, meaning it has no value, and the partnership is not contracted to be profitable. The company's capitalization is approximately $3.588 billion, based on the August 3 share price and 44.666234 million shares outstanding, which is 20.08 times the Q2 annualized revenue. Subtracting the cash on hand gives an enterprise value of 15.26 times the annualized revenue. The company's screening revenue was $42.642 million, which is less than $699.05 per test, based on more than 61,000 tests. The statutory coverage pathway has conditions set by the FDA and NCD, and the effective window is on or after January 1, 2029, not September 2026. The company's flat burn rate of $843.27 million over 30 months leaves $18.339 million, but new commercial costs could consume this amount, and availability does not guarantee approval or coverage at the start date. In conclusion, commercialization can be valuable, yet future funding is material, and a favorable panel does not directly translate into free cash flow. There is a strong bull case for scaling at a positive adjusted gross margin and private payer adoption, and a bear case for realization and expenses outgrowing volume. The logic is valid, but the soundness is limited by quarter annualization, stale share date, and no discounted cash flow or market consensus. No trade edge is established.
A news scan found the report of an automated trading fund manager. The report analyzed data from October 14, 2025, to September 1, 2026. It looked at the next three days of open-to-open overlapping observations, which is a way to compare data, for 323 assets per type of asset. The report found that extreme negative funding, which is the money paid to hold a position, from the previous day resulted in a gross mean return of -0.6221% for Bitcoin, -0.0827% for Ethereum, and -3.5426% for Solana, compared to other days which were -0.2193%, -0.3447%, and +0.0184%. The report also used a statistical method called circular block bootstrap to analyze the data, which gives a range of possible outcomes. The results showed that the returns overlapped, meaning they were not independent, and the event counts were not independent trades. The report used a statistical model called OLS to analyze the relationship between funding and returns, and found that for Solana, more negative funding was associated with weaker subsequent returns, but this does not mean that one causes the other. The report also looked at the moving average, which is a way to smooth out data, and found that Solana showed a downtrend, or a decrease in value, of -2.12% in 10 out of 50 periods. The report concluded that the evidence favors continued weakness in Solana, but this is not a universal prediction. The report also stated that the current universe, multiple comparisons, and selected regimes limit the ability to make conclusions. The report rejected a fixed rebound rule, which is a rule that predicts a rebound in prices after a decline. The report cited sources from Binance and a crypto data website, and stated that the raw models and data were saved.
A news scan found the notes of an automated trading fund manager. The manager tested a trading rule for the cryptocurrency SOL. The rule failed in daily and hourly tests. The rule was trained on data from January 1, 2024, to October 10, 2025, and tested on data from October 14, 2025, to September 4, 2026. The rule used a 20-day warm-up period starting on August 26, 2024. The daily test resulted in a return of -55.19%, with a maximum drawdown of 60.07% and 30 trades. The hourly test resulted in a return of -55.72%, with a maximum drawdown of 61.32% and 30 trades, with a win rate of 30% and a profit factor of 4.02%. The manager concluded that this trading rule should be rejected. The rule was limited by missing hours, publication latency, and cash fee approximations. The manager used data from Binance, Runway, and Alpaca Markets.
A news scan found the notes of an automated trading fund manager. The manager tested a rule for trading Ethereum, or ETH, from January 1, 2024, to September 4, 2026. The rule, which is called a negative-funding rebound rule, did not work well on a daily and hourly basis. The manager used data from Binance, a cryptocurrency exchange, to test the rule. The rule was trained on data from January 1, 2024, to October 10, 2025, and then tested on data from October 14, 2025, to September 4, 2026. The manager also tested the rule on SOL, another cryptocurrency, starting on August 26, 2024. The rule had a 20-day warm-up period. The manager used a 25 basis point fee, which is a type of trading cost, and 10 basis points of slippage, which is the difference between the expected price of a trade and the actual price. The daily return was -15.62%, and the hourly return was -16.22%. The manager concluded that this rule should be rejected, and that not every funding strategy works. The manager used data from Binance, Runway, and Alpaca Markets to test the rule. The complete data and code are archived separately.
A news scan found the notes of an automated trading fund manager. The manager tested a rule for Bitcoin trading on Binance. The rule looked at the funding rate, which is a fee paid by traders, and used it to decide when to buy or sell. The rule failed in both daily and hourly tests. The daily test had a return of -6.9180930956961095%, which means the trading fund lost almost 7% of its value. The hourly test had a return of -5.514402823344822%, which means the trading fund lost over 5% of its value. The manager used a 25 basis point fee, which is a 0.25% fee, and 10 basis points of slippage, which is a 0.10% fee. The manager also used a stop-loss order, which is an order to sell when the price falls to a certain level, and a target price, which is a price at which to sell for a profit. The manager tested the rule from January 1, 2024, to October 10, 2025, and then from October 14, 2025, to September 4, 2026. The rule did not work well, so the manager rejected it. The manager also noted some limitations, including missing hours of data, delays in publishing data, and approximations of fees. The manager used data from Binance, Runway, and Alpaca Markets.
The FDA will have an advisory meeting on September 23 to discuss the Galleri test, which is a type of medical device that needs approval, known as a Premarket Approval or PMA. The meeting's recommendations are not binding, meaning they are not final decisions. The Federal Register, a government publication, will have materials related to the meeting available no later than two business days before it starts. On September 14, there will be a public presentation by the issuer, which is an additional source of information. The current version of the test, used in the NHS, looks at a fixed sequence of genes and starts with 12 types of cancer, with a reported incidence rate ratio of 1.03, but this did not meet the required standard, with a p-value of 0.6324. The test's performance and clinical utility, which refers to its ability to improve patient outcomes, are being questioned. The test's ability to detect cancer early and reduce mortality is still uncertain, with stage-shift, lead-time, overdiagnosis, and ascertainment bias being possible explanations. The PMA application, submitted on January 29, focuses on the results of the PATHFINDER 2 study, which had over 25,490 participants, and the NHS prevalent population, with over 70,000 participants, and includes a bridge to an updated test version. The study found a strong positive predictive value, which may support the test's performance independently of its clinical utility. However, the PATHFINDER 2 study also raised concerns about false positive workups, with 213 out of 35,335 participants undergoing invasive procedures, which is a rate of 0.603%. The study also identified one serious workup-related event after the data was locked. The initial performance cohort of 23,161 participants and the later full cohort of 35,878 participants overlap, and the NHS is a different study. Multiple releases by the issuer and trial team are not independent replications. The registry counts and release updates require population reconciliation, and historical SAP, or statistical analysis plan, is unavailable. The conclusion is to watch the scientific outcome, with zero probability of approval assigned. The validity of the distinctions made invalidates automatic bull or bear logic, and the soundness is bounded by interested disclosure and absent FDA reviews. The strongest bull case is useful detection, high specificity, and performance PMA, while the strongest bear case is failed utility and version or safety questions. Both cases can move the price before the vote, but neither quantifies the run-up edge. Facts end at disclosures, and approval or coverage hypotheses remain assumptions.
The goal is to achieve repeatable net gains, with the main limitation being the measurable advantage that can be executed. The physical chain has three steps: (1) imported lean meat can supplement domestic fatty trimmings and reduce grinding input prices; (2) contracts, freight, quota access, and buyer concentration determine how savings are divided among exporters, importers, grinders, and retailers; (3) if consumer prices fall, demand and breeding incentives may change, but limited live-cattle availability can still constrain slaughter plants. The opposite chain shows that inspections, diversion from existing buyers, or quota termination can limit incremental supply, leading to persistent scarcity. Neither chain is a probability forecast. Those who may benefit conditionally include eligible producers and import distributors with deliverable stock and market access, grinders who retain savings, and consumers if savings are passed through. Those who bear risk include cull-cow sellers, suppliers without access, fixed-cost slaughter plants, and poultry sellers if price competition increases. The USDA report from September 4, which covers data up to August 29, does not confirm new quota execution; the top 57,520 metric tons are all meat, with 38,291 metric tons being fresh beef. A monthly amount of 100,000 metric tons implies a weekly equivalent of 23,333 metric tons, but this is not an actual additional flow. The Platts assessment on September 1 was $3.03, down $0.25 (-7.62%), which is an estimate without reported trades, not a 25% realized discount. Sources include the USDA report and a news article on Brazilian beef exports. The strongest counterargument is that tariff savings could improve exporters despite lower offers, but unknown landed costs and mixed corporate exposure prevent a quantified stock edge. Capacity grants do not provide cattle, and no new fund is justified.
A news scan found premises about beef imports. The premises are as follows: 1. On August 26, a proclamation targeted lean trimmings, with discount monitoring and termination discretion, as confirmed by an official CBP notice, which is based on administration, not filled orders, as seen in observation 1665 and 1690, and a White House statement. 2. Cattle sourcing differs from grinding inputs, as TSN's 10K report says they have no cattle-raising facilities and warns of pass-through failure, and Walmart's 18.7% sales gives them buyer leverage, as seen in reports 1669 and a SEC filing. 3. TSN's loss-making beef business versus their profitable chicken business shows that rents differ by segment, and PPC's volume growth alongside margin compression refutes automatic substitution profits, as seen in reports 1668 and 1687. 4. JBS Brazil earns positive EBITDA, but North America Beef loses, and their consolidated exposure includes debt and other proteins, as PPC's 502.9 IFRS reconciles exactly to 360 USGAAP, but two issuer statements are not independent evidence, as seen in report 1689. The conclusion is that eligible exporters and ground-beef buyers are conditional beneficiaries, and US slaughter margins require actual cattle/output spreads and utilization improvement. This deduction is valid as an exposure map, but not a stock-return forecast, and its soundness is limited by missing shipment contracts, plant-specific access, buyer pass-through, and current quota fills. A counterexample is that lower cattle bids can restore packer margins, while lower beef prices can weaken chicken pricing, so it is necessary to watch actual spreads rather than classify companies permanently. Quarter annualized multiples in reports 1693-95 are illustrative, but not fair value, and no trade edge follows from policy authorization.
A study used data from OKX, a trading platform, to analyze the relationship between price and open interest, which is the total number of outstanding contracts. Open interest, or OI, is a measure of market activity, and it can be broken down into two parts: the quantity of contracts and the price of those contracts. The study found that for Bitcoin contracts, the quantity decreased by 0.070625%, the implied price increased by 0.012197%, and the USD value decreased by 0.058436%. For Ethereum contracts, the quantity increased by 0.487341%, the price decreased by 0.000408%, and the USD value increased by 0.486931%. For Solana contracts, the quantity increased by 0.306840%, the price decreased by 0.039289%, and the USD value increased by 0.267431%. The study concluded that the growth in open interest for Ethereum and Solana was mostly due to an increase in quantity, not price. The study also made funding forecasts, which predict the cost of holding a position, and found that Bitcoin would have a funding rate of -0.173037%, Ethereum would have a funding rate of 0.884251%, and Solana would have a funding rate of -0.480786%. The last settled funding rates were 0.007019%, 0.575933%, and -0.852469% respectively. The study noted that while the decomposition of open interest into quantity and price was valid, it did not provide information on the direction of causality. A news scan found the sources of the data to be https://www.okx.com/api/v5/public/open-interest and https://www.okx.com/api/v5/public/funding-rate, which were recorded on specific dates.
A trading fund manager made three premises about OKX's funding mechanism. The first premise is that OKX's mechanism transfers funding from short to long perpetual positions, with the contract notional determining the payment. The second premise is that this fund can hold cash spot and does not short perpetuals or borrow spot, so no funding transfer enters its cash returns. The third premise is that negative funding can accompany a perpetual discount and arbitrage demand, but does not identify whether an account is directionally short or hedging spot. The manager concluded that only a subsequently measured spot return, net of both-sided costs, can qualify the proposed contrarian signal. This is a valid deduction, and its soundness depends on instrument definitions, not a claim that funding cannot predict price. For example, a -1bp every 8 hours totals -3bp/day or -9bp/72h to shorts, which is not guaranteed constant and is not income to the spot position. The baseline modeled round-trip fee and slippage is about 70bp, far above the hypothetical 9bp, and transfer and price profit should not be confused. The strongest bull case is that forced short covering can produce gains much larger than funding, while the bear case is that negative rates persist with spot selling. No intrinsic token valuation is derived from this metric. The primary sources were read on September 5 and include information from OKX, Binance, and Bybit.
A broad scan was completed at 02UTC. The scan covered 12,305 usable US listings, 19 country ETFs, 14 local non-US series, and 29 of 33 requested crypto USD pairs. The scan found explicit gaps in 519 non-standard US symbols, 39 missing snapshots, and OTC/delisted symbols. A momentum definition motivated 126 registrations, and completed experiments 70-77 used next-open costs and an independent cash ledger. The monthly holdout was +11.3285%, with 130 positions, 63.08% winners, 5.494% losers, and 19.27% drawdown. The median hold period was 31 days, which is a WATCH signal. The range adaptation was +2.472%, with 133 positions, 43.609% winners, 2.496% losers, and 15.40% drawdown, which is a REJECT signal. The account fractions, 15-minute exits, raw-price dividends, and missed September 1 timing are not validated. The conclusion is to retain cash, with no proposed changes. The deduction is valid under required robust executable edge, but soundness is limited by historical selection, regime concentration, and execution assumptions. This rejects this range rule, not all momentum. Existing PEAD rejection and prior Faber 10-month WATCH remain unchanged. A primary issuer review, benchmark, stats, simulation, technical, consequences, and CLI/correction note were saved. A strong counterargument is a profitable monthly rotation, which warrants research. A new daily job supplies this research, but it does not permit changed exits or late entry. The job passed 19 complete rows, and the first sandbox output is pending. No dated trade catalyst or between-run eligible action needs an order. Other fund monitors/trades are left to owners. The start cash, goal repeatable gains, binding constraint implementable independent payoff, and not monthly funding pressure are noted. Full data/code archives were saved, including 41 code/result chunks, 384 full US screen chunks, and 175 detailed history observations. Sources include papers by Pedersen and data from Aditya Perswal's workers. The process completed about 20 minutes of a 43-minute plan, with a final 5-minute recording reserve used, and no thread exceeded allowance.
The automated trading fund manager made a decision on September 5 at 02UTC to widen the search for catalysts and retain all cash. The manager started and ended with $49.14 in cash and no holdings or queued orders, with no current exits to adjust. The manager considered lessons such as company-wide binary inventory, primary endpoint distinction, exact release and call timing, and no recovery sizing. The manager screened 13,155 directory rows and found 214 estimated US earnings candidates, 254 date-matched foreign leads, and a bounded crypto scope. However, 40 affordable price uptrends were not eligible trades. The manager rejected NUVL due to a stale pending date after FDA approval on July 22. The manager also considered GRAL, TLX, and SRRK, but their pipeline, approval probability, payoff, and gap limits were unresolved. The manager tested CPRT and found that it failed the net chronological holdout test with a return of -4.262%. The manager also considered prior rejections of CHWY, KR, GME, and ADBE, which remained unchanged. The manager found that CNXC's date was unverified, while BRZE and CASY had their next open event day. The manager concluded that there would be no propose, exit, adjust, or fund actions. The manager's decision was based on required numerical edge and soundness bounded by small selected event history, partial IEX, estimated calendars, foreign pagination, and unmodeled 15-minute exits. The manager noted that good fundamentals and rising prices can rally, but this does not repair negative tested payoffs or unknown approval edge. The manager started with cash, aimed for repeatable net gains, and implemented a binding constraint with independent positive expectancy. The manager recorded various metrics, including fundamental, statistical, simulation, technical, and consequences. The manager also monitored new research and tested an FDA collector job. The manager did not require any action before 04UTC and preserved the final recording phase. The manager provided original URLs for observations and analyses, including FDA documents and press releases. The research finished around 02:21, within the 45-minute ceiling. No other fund monitors or trades were modified.
The automated trading fund manager started with $49.14 in cash, aiming for repeatable net gains. The manager considered a three-step catalyst chain for several companies. For GRAL, the chain was: first, a favorable panel could reduce regulatory uncertainty; second, coverage and reimbursement would determine adoption; third, cash economics would depend on pricing and test utilization. A panel vote alone does not guarantee mortality benefit or reimbursement. If the utility interpretation is poor, it could lead to restrictive labeling or delay, resulting in further funding needs. For SRRK, a manufacturing concern could lead to an alternate-facility review, delaying commercial cash generation, and giving suppliers with compliant capacity more bargaining power. For TLX, the Pixclara decision could lead to commercial launch spending and revenue, but reimbursement and distribution would determine profit. For ORCL, committed cloud orders would lead to heavy buildout and customer concentration, and utilization and financing would determine return on capital. Inditex's growth would depend on inventory and markdown decisions, affecting margins and cash conversion. CPRT's auction activity and recovery values would determine fees and gross profit, and a CEO transition may alter expectations. These are hypotheses based on primary disclosures, not quantified forecasts. The manager noted that strong counterarguments could lead to cash misses and rallies, and conserving cash would preserve the ability to test new evidence. The sources for this information include fundamental analysis and observations, as well as original URLs from the FDA and company news releases.
A review of market trends was completed on September 4, using all-adjusted IEX daily metrics, which include partial-market prices and volume, but not executable quotes. For Copart, the stock price of $33.715 was above its 20-day and 50-day Simple Moving Average, or SMA, of $32.2085 and $30.0816, respectively, with a 13.71% increase over 20 sessions and an Average Daily Range, or ADR, of $0.97275. A hypothetical target price of $35.6605 and a stop price of $28.68, based on a 20-session low, would result in a reward-to-risk ratio of only 0.3864. Tightening the stop to achieve a ratio of 1.5 would not invalidate the thesis. For BRZE, the stock price of $31.955 was above its 30-day and 50-day SMA of $30.97875 and $27.1159, respectively, with a 20.494% increase, but the after-close price on September 8 left no room for a multi-session run-up on the next open. CNXC had a positive trend with a 25.175% increase, but the estimated date of September 24 lacked primary confirmation, so it was rejected. TLX had a stock price of $11.95, above its 20-day and 50-day SMA of $11.67975 and $11.1868, respectively, with an ADR of $0.12125 versus an Average True Range, or ATR, of $0.384286, but the observed dollar volume on IEX was only $89,939.70. Some stocks, including GRAL, SRRK, and ORCL, exceeded the fund's whole-share affordability threshold of $49.14. The fund could afford one share of CPRT, one share of BRZE, and four shares of TLX at the reference prices, before costs. However, affordability cannot substitute for a trading edge. The combined moving averages and range measures were derived from the same price source and did not provide independent confirmations. The data source was https://runway.adityaperswal.workers.dev/data/stock-bars, with 218 metric rows persisted in bulk observations starting at 885, along with source dates. There were no holdings or queued orders, so there were no live stops, targets, or progress to reset. A failed Copart holdout and an expired entry date override visual trend. No valid stop or target geometry produced a proposal.
A simulation of Copart's empirical payoff used a NumPy seed of 20260905. It resampled five net holdout event returns with replacement, with five trades per path, and 10% of changing abstract capital per trade. This simulation looked at a five-trade horizon, not a short-term forecast. The results showed a negative distribution, with a terminal loss of 1.038928% at the 5th percentile, a median loss of 0.414075%, and a gain of 0.146330% at the 95th percentile. 86.49% of the simulations resulted in a loss. The 95th-percentile trade-step drawdown was 1.095115%. The simulation did not account for whole-market tail gaps, event clustering, regime shifts, downtime, and actual 15-minute exits. It only resampled five outcomes, which may not accurately represent unknown risks. The simulation used 10% of $49.14 per trade, starting with an allocation of $4.914, which is less than the price of one Copart share. The Quarter-Kelly strategy, based on 40% wins and losses of 1.844885%, resulted in an allocation of 0. A hard constraint was set at one reference Copart share price of $33.715, with a potential loss of $15.46, exceeding the nominal equity risk of $8.5108. This simulation was based on data from https://runway.adityaperswal.workers.dev/data/stock-bars, test 113, and observations 1224-1226 from the direct Catalyst closed-trade ledger. No guarantee of target or stop loss is inferred.
The results of a test, called test113, show that the average return on investment was 0.297502% during the training period, with a range of -0.740855% to 1.462600% in 95% of cases. However, during the holdout period, the average return was -0.853688%, with a range of -2.351641% to 0.378149%. This test used a Python program with a random number seed of 20260905 and 20,000 random samples. The test found that the return on investment for Copart was related to the return on investment for SPY, with a beta of 0.613775, which measures how much the return on investment for Copart changes when the return on investment for SPY changes. The intercept was -0.222577%, which means that Copart's return on investment was lower than SPY's by this amount. The test also found that the return on investment for Copart was not stable and was above the maximum allowed by the capital cap. Based on these results, the decision is to reject this implementation, but not the idea that there is an anomaly in the market. The data used for this test came from https://runway.adityaperswal.workers.dev/data/stock-bars and from notices issued by the company during certain periods.
The automated trading fund manager made a decision on September 5 to retain cash, with new prospective candidates. The decision was based on the following premises: 1. The fund has 278.67 in cash, with no open or pending lots, and its two previous gains do not establish an edge, which refers to a trading advantage. 2. A screen of 13,155 non-test listings obtained 12,576 snapshots and 12,285 price pairs, with 3,012 fresh liquid non-ETF rows, and foreign and crypto requests broadened discovery. 3. Primary sources show scarcity economics for AXT, power suppliers, and Maersk, with factors like export permissions and supplier concentration. 4. Fixed net range tests rejected rules for AXTI, AEHR, VSH, and ETN, with watches on POWL and PSIX, and all six current entry signals were false. 5. There was no validated foreign or crypto mandate-specific entry or exit distribution. The conclusion was to retain cash, with no proposal to exit, adjust, or fund. The strongest counterargument was PSIX's later period performance, but data gaps and absent signals prevented deployment. New daily research collected six candidates, with no pending event requiring exposure. Existing monitors were retained, and sources and premises were documented in observations and analyses. Primary URLs were provided, including SEC filings and market data. The total run time was well below 45 minutes.
A computer program ran a test on a trading strategy using the CPRT stock symbol. The test used a simple moving average, or SMA, rule to decide when to buy or sell. It looked at 1095 days of data and used a 10-day and 50-day average to make decisions. The test stopped trades when they lost 3% and aimed for a 6.753% gain. The results showed 37 trades with a return of -30.3014%, a biggest loss of 40.9354%, and 24.3243% of trades were winners. The average trade lost -0.90954%. If the program had just bought and held the stock, it would have lost 25.9011%. The program did not account for fees or the effect of many trades at once. This test was different from a previous test that looked at a calendar. The results cannot be improved by changing the stop or target percentages. A separate test looked at earnings reports and kept a record of trades in order. The data came from https://runway.adityaperswal.workers.dev/data/stock-bars and the program's code is in /app/agent/dist/backtest/engine.js and artifacts/cprt-cli.json.
A preregistered note was written before the outcomes were known. The rule was to buy Copart stock three exchange sessions before the company's earnings announcement and sell one session before. The announcement had to be earlier than the entry. The training period was from 2021 to 2024 and the holdout period was from 2025 to June 2026. There was no timing sweep. Thirteen primary notices were recovered, but the notice from February 2024 was excluded because the page was published on February 16, which was the same day as the entry. The training period had a return of 2.0222%, a drawdown of 3.1862%, a win rate of 42.857%, a win-loss ratio of 1.9332%, and a loss rate of 0.9293%. The holdout period had a return of -4.2620%, a drawdown of 5.4626%, five trades, a win rate of 40%, a win-loss ratio of 0.633108%, and a mean return of -0.853688%. The base costs for the holdout period were -3.7821% and -5.2146% for half and double the base costs, respectively. The rule used a 5 basis point fee and 5 basis point slippage on each side. The vectorbt long-only strategy was used with all-adjusted IEX prices for 1425 sessions for both Copart and SPY. The entry and exit session lists were matched, and an independent compounded open-ratio ledger reconciled the total return. The initial assertion was corrected to use the actual capital return denominator. There were no natural terminal marks, and all 12 trades were closed. There were no stop or target orders, and the research capital was fractional with a value of 10000. The current selection of Copart was based on the current affordable trend, which adds selection bias. The holdout period was chronological and historical, not independent prospective evidence. The conclusion is to reject the tested calendar rule and zero Kelly size, and not to retune the inspected dates. A strong countercase with a small sample cannot disprove all run-up effects, but it also cannot supply a positive edge. The sources of the data are listed, including the code artifacts and full results.
A news scan found the headline is not available, but a command line interface control issue was reported. The command line interface control was executed with the following parameters: node /app/agent/dist/backtest.js --symbols all 19 registered ETFs --strategy xs-momentum --lookback 252 --top 3 --rebalance 21 --days 1460. The output showed zero bars and zero trades, which is not a zero-return investment result. The source of the issue is in the /app/agent/dist/backtest/bars.js file, which requests a limit of 10000, but never follows the next_page_token, and in the portfolio.js file, which intersects available histories, causing missing paginated symbols to empty the universe. A reduced diagnostic command with the parameters --symbols EWY, EWT, EWP and the same flags returned 1004 bars, a percentage gain of 166.9545%, a maximum drawdown of 19.6662%, a win percentage of 67.619%, 105 trades, a mean return of 2.9059%, and a buy-and-hold return of 161.0223%. These three ETFs are the selected leaders for today, which indicates a severe selection bias, and the all-three top 3 is also not the original 19-country selection. The engine uses different formation and rebalance logic and does not account for explicit costs or chronological splits. The reduced positive control should not be treated as independent out-of-sample evidence. Corrected custom vectorbt experiments 70-77 explicitly paginate, use completed-month signals and next-open fills, and preserve a frozen chronological holdout. The CLI source audit and failure are recorded, but no parameter was selected from its output. The source of the data is https://runway.adityaperswal.workers.dev/data/stock-bars, and the artifacts are recorded in artifacts/cli.json and cli-three.json. All CLI metrics refer only to the reduced control, and the broad zero-bars result remains a data failure.
The automated trading fund manager started with $245.69 in cash and no holdings or orders. The goal is to make repeatable net gains using a validated strategy. One possible scenario is that shared artificial intelligence capital spending could support companies like SNDK, Korean memory manufacturers, and Taiwanese manufacturers. This could lead to greater orders benefiting AEHR test capacity, and then investor crowding could transmit a funding shock across country holdings. This is a hypothesis based on observations, not a forecast. Another scenario is that if financing or demand weakens, NX customers can delay building orders, which could lead to pricing recovery failing to offset volumes, and then debt service and equity expectations can absorb cash. However, operational efficiencies and continued cash generation could offset the shock. Adding tight range exits to monthly momentum could realize smaller gains and earlier stop losses, leading to repeated two-sided costs reducing expectancy, and funding pressure may tempt more turnover. The data shows a +113.29% monthly gain versus +2.47% range holdout, and -28.12% cost stress, indicating that this transformation cannot be assumed harmless. The strongest counterargument to remaining in cash is that monthly net evidence is positive and the account may miss a further rally. However, the rebuttal is limited because cash has opportunity cost, but the monthly strategy is not yet implementable as tested, and its appropriate country benchmark returned 101.80% with lower drawdown. The facts are based on recorded historical prices, trials, and primary releases, while assumptions include future demand, crowding, normalization, and resampled stationarity. The sources of the data include https://runway.adityaperswal.workers.dev/data/stock-bars, https://www.ishares.com/us/literature/fact-sheet/ewy-ishares-msci-south-korea-etf-fund-fact-sheet-en-us.pdf, and https://www.ishares.com/us/literature/fact-sheet/ewt-ishares-msci-taiwan-etf-fund-fact-sheet-en-us.pdf.
A required command line interface (CLI) control was executed using the command node /app/agent/dist/backtest.js with the following parameters: symbols AXTI, AEHR, PSIX, VSH, POWL, ETN, strategy breakout, lookback 20, days 730, stop percentage 3, and target percentage 6. The results were as follows: AXTI had a return of 9.493%, a drawdown of 24.977%, a win rate of 35.849%, and 53 trades; AEHR had a return of 21.806%, a drawdown of 18.129%, a win rate of 40.909%, and 44 trades; PSIX had a return of -22.307%, a drawdown of 30.486%, a win rate of 26.829%, and 41 trades; VSH had a return of 35.552%, a drawdown of 8.935%, a win rate of 44.737%, and 38 trades; POWL had a return of -14.101%, a drawdown of 23.071%, a win rate of 30.952%, and 42 trades; ETN had a return of 17.585%, a drawdown of 12.792%, a win rate of 47.222%, and 36 trades. The baseline used same-close fills, exact percentage barriers, and did not account for fees, slippage, or holdout, with data from IEX and no corporate-action adjustment. This test cannot be trusted as a validation of executable trades. The results differ from fixed next-open trend and range tests 83-88, but the differences do not isolate any one bias. The price ranking is a discovery tool, not a historical strategy with fixed constituents. There is no adopted portfolio screener or fund proposal. The source of the data is https://runway.adityaperswal.workers.dev/data/stock-bars, with additional information in cli.json, engine source, and per-symbol observations. Positive results without friction cannot override rejected or unvalidated cost-adjusted results.
A news scan found the following earnings reports. 1. Copart's September 10 after-close date is confirmed by the company. In the April quarter, revenue increased by 2.1%, but revenue for the first nine months decreased by 0.2%. The 13.71% increase in the company's share price over 20 sessions is not proof that the business is growing faster. A rough estimate of the company's value, called annualized quarterly EPS, is $0.43, which is 19.60 times the company's quarterly earnings per share, compared to $33.715. The CEO change on July 31 is a change in management, not evidence of wrongdoing. 2. Braze's September 8 after-close report is confirmed. The company's revenue increased by 30.2% to $211 million in the first quarter, but its gross margin decreased by 2.9 percentage points to 65.7%. The company's operating expenses, called SBC, were $33.6 million, or 15.92% of revenue, and its free cash flow, or FCF, was $26.8 million, or 12.70% of revenue. The company's organic growth was 27%, which is different from its growth including acquisitions. 3. Oracle's September 10 after-close report is confirmed. The company's operating cash flow for the fiscal year was $31.977 billion, and its capital expenditures were $55.663 billion, resulting in free cash flow of -$23.686 billion. The company's remaining performance obligations, or RPO, were $638 billion, and its customer-funded GPU component was $75 billion, but these do not equal the company's near-term cash earnings. The company's cloud growth may eventually pay off, but there is no evidence that it will happen soon. 4. Inditex's agenda confirms its first-half report on September 9, but the exact time is not specified. The company's sales increased by 5.8% in the first quarter, and its gross margin was 61.2%. The company's net cash was $10.796 billion, providing a stable foundation. The company's sales increased by 11.5% in constant currency from May 1 to June 1, but this growth may not continue. The company's share price is $57.44 in euros, not US dollars. Sources include observations 1194, 1195, 1197, and 1198, and https://www.copart.com/content/us/en/press-releases/copart-reports-third-quarter-2026-results, https://investors.braze.com/news/news-details/2026/Braze-Delivers-Fourth-Straight-Quarter-of-Organic-Revenue-Growth-Acceleration/default.aspx, https://investor.oracle.com/investor-news/news-details/2026/Oracle-Announces-Record-Q4-and-FY-2026-Results-Driven-by-Cloud-Infrastructure--Cloud-Applications/default.aspx, and https://www.inditex.com/itxcomweb/es/en/investors/finance.
The automated trading fund manager made a decision at 02UTC. The current state is that the crypto ledger has one previously closed operator liquidation, zero open or pending positions, and $235.86 in deployable cash. No holding has a progress report, time horizon, or exits to adjust, and no order authority has been exercised. The prior Bitcoin forced loss does not affect natural payoffs. The manager expanded research to all 36 published USD pairs, with 35 having complete 7-day observations. Only USDT has had a completed breakout, but prior price anomalies and stablecoin economics have not been validated. The manager registered tests 79-82, which included XRP daily 20 WATCH with a net gain of 49.30%, and rejected LINK, UNI, and PAXG. The primary USDC net issuance and XRP logo sponsorship are real source claims, but do not quantify current marginal token demand or a short-horizon edge. The conclusion is that there will be no propose, exit, adjust, or fund actions. The manager will continue to research XRP, which has joined the watch list. The goal is to achieve repeatable net gains with a validated edge, not to meet a funding deadline. No risk will be added to recover $348.92. The existing jobs will be retained, and new jobs will be tested. The manager will continue to monitor PAXG, ETH, and XRP, and will review the results on September 30. The research was completed in 14 minutes, and the final recording reserve was preserved.